AstraZeneca, Harvard Partner in Diabetes Research

AstraZeneca has entered into a five-year research collaboration with the Harvard Stem Cell Institute (HSCI) to adapt a technique that creates human beta cells from stem cells for use in screens of AstraZeneca's compound library in the search for new treatments for diabetes. The collaboration also aims to better understand how the function of beta cells declines in diabetes, and research findings will be made available to the broader scientific community through peer-reviewed publications.

In people with Type 1 diabetes, beta cells are destroyed by an autoimmune response and patients must inject insulin to maintain normal blood glucose levels. In Type 2 diabetes, the beta cells either fail to function properly or their numbers decrease. Human beta cells for research are extremely limited in number and availability. However, a team led by HSCI co-chairman and Howard Hughes Medical Institute Investigator, Professor Doug Melton, has developed a technique which allows quantities of beta cells to be produced from human induced pluripotent stem cells generated directly from adult cells, similar in all important respects to those found in healthy individuals.

Under the agreement, AstraZeneca will provide funding for a team of investigators at HSCI lead by Professor Melton as well as establishing an in-house team in Mölndal, Sweden, dedicated to the collaboration. Scientists from each organization will work together to understand the biology behind the loss of human beta cell function and mass in diabetes, and to screen compounds against the cells produced to search for potential new medicines that could restore beta cell activity in diabetic patients.The collaboration is aligned with AstraZeneca's strategic research approach in diabetes which is aimed at restoring the function of the pancreatic beta cells as well as insulin sensitivity, irrespective of therapeutic modality.

Source: AstraZeneca

Leave a Reply

Your email address will not be published. Required fields are marked *